Answers are grounded in this paper and cite their sources.
Objective: Semaglutide, a GLP-1 receptor agonist (GLP-1RA), improves blood glucose control and promotes weight loss. This study aimed to elucidate the background characteristics, glycemic control outcomes, and body composition changes in patients who were administered semaglutide injections at St. Marianna University Hospital (Kawasaki, Japan), particularly focusing on evaluating the fibrosis-4 (FIB-4) index to investigate its potential association with weight loss outcomes.
No takes yet. Share an insight, caveat, or question.
Nakagawa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: